So when should RAAS blockers be stopped ... as well as bilateral renal artery disease or -- more importantly and underappreciated -- intrarenal vascular/ischemic disease, which can look like ...

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the completion of enrollment for its Explore-CKD Phase ...

CKD screening at age 55, combined with SGLT2 inhibitors, reduces kidney failure incidence and improves life expectancy across racial and ethnic groups. Non-Hispanic Black adults experience the ...

The incidence of hyperkalemia in patients with normal renal function who are treated with dual RAAS inhibitors in the absence of other potassium-retaining therapies seems to be approximately 5%.